Добірка наукової літератури з теми "APR-246"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "APR-246".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Статті в журналах з теми "APR-246"
Jonsson-Videsater, Kerstin, Dina Ali, Hareth Nahi, Sofia Bengtzen, Stefan Deneberg, Christer Paul, and Soren Lehmann. "In Vitro and Ex Vivo Studies On Cell Lines and Primary Human Leukemia Cells of the Effects of APR-246 Alone and in Combination with Conventional Chemotherapeutic Drugs." Blood 114, no. 22 (November 20, 2009): 2751. http://dx.doi.org/10.1182/blood.v114.22.2751.2751.
Повний текст джерелаCeder, Anna Sophia, Sofi E. Eriksson, Emarndeena Haji Cheteh, Vladimir J. N. Bykov, Lars Abrahmsen, and Klas G. Wiman. "Impact of combined MRP1 inhibition and mutant p53-targeting compound APR-246." Journal of Clinical Oncology 37, no. 15_suppl (May 20, 2019): e14712-e14712. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.e14712.
Повний текст джерелаMüller, Michael, Lisa Rösch, Sara Najafi, Charlotte Gatzweiler, Johannes Ridinger, Xenia F. Gerloff, David T. W. Jones, et al. "Combining APR-246 and HDAC-Inhibitors: A Novel Targeted Treatment Option for Neuroblastoma." Cancers 13, no. 17 (September 5, 2021): 4476. http://dx.doi.org/10.3390/cancers13174476.
Повний текст джерелаHong, Yuheng, Tianyuan Ren, Xiaoxuan Wang, Kai Fu, Xianhuo Wang, and Huilai Zhang. "APR-246 Reveals a Therapeutic Potential Via Triggering Different Cell Death Mechanisms in Diffuse Large B Cell Lymphoma." Blood 138, Supplement 1 (November 5, 2021): 3521. http://dx.doi.org/10.1182/blood-2021-150582.
Повний текст джерелаSynnott, Naoise C., Alyson M. Murray, Norma O'Donovan, Michael J. Duffy, and John Crown. "Combined treatment using the anti-p53 drug, APR-246 and eribulin: Synergistic growth inhibition in p53-mutated breast cancer cells." Journal of Clinical Oncology 35, no. 15_suppl (May 20, 2017): e14098-e14098. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e14098.
Повний текст джерелаXin, Qian, Qinghong Ji, Ying Zhang, Weihong Ma, Baoqing Tian, Yanli Liu, Yunsong Chen, et al. "Aberrant ROS Served as an Acquired Vulnerability of Cisplatin-Resistant Lung Cancer." Oxidative Medicine and Cellular Longevity 2022 (June 20, 2022): 1–17. http://dx.doi.org/10.1155/2022/1112987.
Повний текст джерелаMohell, Nina, Charlotta Liljebris, Jessica Alfredsson, Ylva Lindman, Maria Uustalu, Thomas Uhlin, Mats R. H. Linderholm, and Klas G. Wiman. "Preclinical Efficacy and Toxicology Studies of APR-246, a Novel Anticancer Compound Currently In Clinical Trials for Refractory Hematological Malignancies and Prostate Cancer." Blood 116, no. 21 (November 19, 2010): 1806. http://dx.doi.org/10.1182/blood.v116.21.1806.1806.
Повний текст джерелаVenkatesh, Divya, Judith Michels, Cailian Liu, Sadna Budhu, Mariam M. George, Lars Abrahmsen, Roberta Zappasodi, Jedd D. Wolchok, and Taha Merghoub. "Abstract 1291: APR-246 enhances tumor immunogenicity even in the absence of p53." Cancer Research 82, no. 12_Supplement (June 15, 2022): 1291. http://dx.doi.org/10.1158/1538-7445.am2022-1291.
Повний текст джерелаNagourney, Adam J., Joshua B. Gipoor, Steven S. Evans, Paulo D’Amora, Max S. Duesberg, Paula J. Bernard, Federico Francisco, and Robert A. Nagourney. "Therapeutic Targeting of P53: A Comparative Analysis of APR-246 and COTI-2 in Human Tumor Primary Culture 3-D Explants." Genes 14, no. 3 (March 19, 2023): 747. http://dx.doi.org/10.3390/genes14030747.
Повний текст джерелаMacha, Shawn J., Balakrishna Koneru, Trevor Burrow, Charles Zhu, Dzmitry Savitski, Jonas Nance, Kristyn McCoy, Cody Eslinger, and C. Patrick Reynolds. "Abstract 6228: APR-246, which restores p53 function, is highly active against alternative lengthening of telomere (ALT) cell lines and PDXs." Cancer Research 82, no. 12_Supplement (June 15, 2022): 6228. http://dx.doi.org/10.1158/1538-7445.am2022-6228.
Повний текст джерелаТези доповідей конференцій з теми "APR-246"
Hernandez, Ana, Codi Mai, Shady Tantawy, Mary Ayres, Zahid Siddik, and Varsha Gandhi. "APR-246 induces ferroptosis and overcomes cisplatin resistance in ovarian cancer." In The MD Anderson Summer Experience 2022. The University of MD Anderson Cancer Center, 2022. http://dx.doi.org/10.52519/00007.
Повний текст джерелаVenkatesh, Divya, Judith Michels, Cailin Lu, Sadna Budhu, Mariam George, Ouathek Ouerfelli, Lars Abrahmsen, Roberta Zappasodi, Jedd Wolchok, and Taha Merghoub. "903 APR-246 induces an increase in tumor immunogenicity in a p53 independent manner." In SITC 37th Annual Meeting (SITC 2022) Abstracts. BMJ Publishing Group Ltd, 2022. http://dx.doi.org/10.1136/jitc-2022-sitc2022.0903.
Повний текст джерелаFransson, Åsa, Daria Glaessgen, Jessica Alfredsson, Klas G. Wiman, Svetlana Bajalica Lagercrantz, and Nina Mohell. "Abstract 1639: Strong synergy with APR-246 and DNA-damaging drugs in primary ovarian cancer cells." In Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-1639.
Повний текст джерелаMohell, Nina, Åsa Fransson, Jessica Alfredsson, Mikael von Euler, Ulf Björklund, and Lars Abrahmsen. "Abstract 2523: Strong synergistic effects with APR-246 and cisplatin in p53-mutant lung cancer cells." In Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-2523.
Повний текст джерелаGhosh, Arnab, Judith Michel, Lauren Dong, Nathan Suek, Hong Zhong, Sadna Budhu, Olivier de Henau, Jedd Wolchok, and Taha Merghoub. "Abstract 4843: TP53-stabilization with APR-246 enhances antitumor effects of immune checkpoint blockade in preclinical models." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-4843.
Повний текст джерелаGhosh, Arnab, Judith Michel, Lauren Dong, Nathan Suek, Hong Zhong, Sadna Budhu, Olivier de Henau, Jedd Wolchok, and Taha Merghoub. "Abstract 4843: TP53-stabilization with APR-246 enhances antitumor effects of immune checkpoint blockade in preclinical models." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.am2019-4843.
Повний текст джерелаMohell, Nina, Jessica Alfredsson, Åsa Fransson, Vladimir Bykov, Mikael von Euler, Klas Wiman, and Ulf Björklund. "Abstract 1801: APR-246, a clinical-stage mutant p53-reactivating compound, resensitizes ovarian cancer cells to platinum compounds and doxorubicin." In Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1538-7445.am2014-1801.
Повний текст джерелаMohell, Nina, Åsa Fransson, Jessica Alfredsson, Mikael von Euler, Ulf Björklund, and Lars Abrahmsen. "Abstract 270: Synergistic effect with APR-246 and standard chemotherapy in small cell lung cancer cells carrying smoking-associated TP53 mutations." In Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.am2016-270.
Повний текст джерелаMohell, Nina, Jessica Alfredsson, Maria Uustalu, Åsa Fransson, Vladimir J. N. Bykov, Klas G. Wiman, and Ulf Björklund. "Abstract 3448: Strong synergistic effects with cisplatin and APR-246, a novel compound reactivating mutant p53, in ovarian cancer cell lines and primary cells from patients." In Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1538-7445.am2013-3448.
Повний текст джерелаSallman, David A., Amy DeZern, Kendra Sweet, David P. Steensma, Thomas Cluzeau, Mikkael Sekeres, Guillermo Garcia-Manero, et al. "Abstract CT068: Phase Ib/II combination study of APR-246 and azacitidine (AZA) in patients withTP53mutant myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-ct068.
Повний текст джерела